Health Catalyst, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Health Catalyst completed the sale of its Vitalware business unit to Med-Metrix, LLC on July 31, 2026, receiving $147 million in gross cash consideration. The company used net proceeds of $145.2 million plus cash on hand to fully repay and retire $159.9 million in principal debt (plus $3.2 million accrued interest and $3.2 million termination fee), eliminating ~$19 million in annual GAAP interest expense. The divestiture removes Vitalware's $17.6 million in revenue (6M 2026) and allows strategic focus on core intelligence products. Pro forma net loss per share improves from $2.07 to $2.04 (6M 2026), and the transaction generated an estimated $65.9 million gain on sale.
Why this rating
Debt elimination ($159.9M principal) is ~62% of company market cap; saves ~$19M annual interest (~7% of 2026 revenue). Vitalware divestiture ($17.6M revenue = 12% of core; $7.5M loss elimination) is meaningful but non-core. Balance sheet transformation and strategic refocus are material relative to company size, though execution risk on intelligence product roadmap remains.
Extracted items
- 2.01 acquisition/disposition
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.